Impurity Control Strategy
Impurity Control Strategy is a systematic, science- and risk-based framework within pharmaceutical development and manufacturing that defines and integrates the procedures, specifications, and controls required to detect, evaluate, and consistently limit process- and product-related impurities in drug substances and drug products to acceptable levels throughout their lifecycle.
130
Publications
4.7K
Citations
647
Authors
189
Institutions
Publications per year
2017–2026
30
Variants
Control Strategy For Impurities
Parents
130
Impurities in Oligonucleotide Drug Substances and Drug Products
Daniel C. Capaldi, Andy Teasdale, Scott P. Henry et al. · Nucleic Acid Therapeutics · 2017 · 130 citations
Krista L. Dobo, Nigel Greene, Michelle O. Cyr et al. · Regulatory Toxicology and Pharmacology · 2006 · 127 citations
Pharmacy, Pharmaceutics, Toxicology +16
1–5 of 130
647
6
h-index
5
h-index
4
h-index
4
h-index
4
h-index
1–5 of 647
189
Eli Lilly (United States)
Indianapolis, United States
10 h-index
36 publications
1.3K citations
AstraZeneca (United Kingdom)
Cambridge, United Kingdom
8 h-index
12 publications
753 citations
Pfizer (United States)
New York, United States
6 h-index
15 publications
2.2K citations

GlaxoSmithKline (United Kingdom)
London, United Kingdom
6 h-index
7 publications
1.2K citations
Takeda (United States)
Deerfield, United States
6 h-index
5 publications
219 citations
Merck & Co., Inc., Rahway, NJ, USA (United States)
Rahway, United States
5 h-index
12 publications
317 citations
Bristol-Myers Squibb (United States)
New York, United States
5 h-index
27 publications
303 citations
Argonne National Laboratory
Lemont, United States
4 h-index
7 publications
130 citations
1–8 of 189
19 publications · 587 citations
13
h-index
15 publications · 385 citations
13
h-index
14 publications · 319 citations
12
h-index
4 publications · 142 citations
4
h-index
4 publications · 300 citations
4
h-index
1–5